<p><strong>Aerovate Therapeutics, Inc.</strong>（纳斯达克代码：AVTE - 获取免费报告）于 4 月 9 日（星期三）宣布了一项股息，纳斯达克股息报告称。4 月 25 日（星期五）登记在册的股东将于 4 月 28 日（星期一）获得每股 2.40 的股息。除息日期为 4 月 29 日（星期二）。</p>
<p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<h2>Aerovate Therapeutics 股票下跌 1.5%</h2>
<p>AVTE 于星期五开盘价为 2.68 美元。Aerovate Therapeutics 的 52 周最低价为 1.25 美元，52 周最高价为 25.29 美元。该公司的 50 日移动平均线为 2.53 美元，200 日移动平均线也为 2.53 美元。该公司的市值为 7768 万美元，市盈率为-0.90，贝塔值为 0.95。</p>
<p>Aerovate Therapeutics（纳斯达克代码：AVTE - 获取免费报告）最后一次公布财报是在 4 月 25 日（星期五）。该公司报告本季度每股收益（EPS）为（0.09）美元，超出分析师一致预期的（0.30）美元，超出幅度为 0.21 美元。股票分析师预计 Aerovate Therapeutics 在当前财政年度将发布-2.64 的每股收益。</p>
<h2>Aerovate Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。该公司专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>高市盈率股票的比较与交易</li>
<li>德州仪器：盈利超预期，乐观指引推动复苏</li>
<li>3 只最佳金融科技股票，助力投资组合提升</li>
<li>O'Reilly Automotive：适合长期投资者的随时购买</li>
<li>消费品股票解析</li>
<li>Chipotle Mexican Grill 在第二季度提供了火热的入场点</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Aerovate Therapeutics 吗？</h2>
<p>在考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aerovate Therapeutics 并不在名单上。</p>
<p>虽然 Aerovate Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AVTE

<p>Aerovate Therapeutics, Inc.（纳斯达克代码：AVTE）宣布每股派息 2.40 美元，将于 4 月 28 日支付给截至 4 月 25 日的股东。除息日期为 4 月 29 日。该公司的股票开盘价为 2.68 美元，市值为 7768 万美元。Aerovate 报告上个季度每股收益为（0.09 美元），超出预期。分析师预计本财年的每股收益为-2.64。Aerovate 专注于开发罕见心肺疾病的治疗，特别是针对肺动脉高压的 AV-101，目前处于 2b/3 期临床试验中</p>

<p><strong>Aerovate Therapeutics, Inc.</strong> (NASDAQ:AVTE - Get Free Report) announced a dividend on Wednesday, April 9th, NASDAQ Dividends reports. Stockholders of record on Friday, April 25th will be given a dividend of 2.40 per share on Monday, April 28th. The ex-dividend date is Tuesday, April 29th.</p>
<div class="lb-trans"><p><strong>Aerovate Therapeutics, Inc.</strong>（纳斯达克代码：AVTE - 获取免费报告）于 4 月 9 日（星期三）宣布了一项股息，纳斯达克股息报告称。4 月 25 日（星期五）登记在册的股东将于 4 月 28 日（星期一）获得每股 2.40 的股息。除息日期为 4 月 29 日（星期二）。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><h2>Aerovate Therapeutics Stock Down 1.5 %</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 股票下跌 1.5%</h2>
</div><p>AVTE opened at $2.68 on Friday. Aerovate Therapeutics has a 52 week low of $1.25 and a 52 week high of $25.29. The business's 50 day moving average is $2.53 and its two-hundred day moving average is $2.53. The firm has a market cap of $77.68 million, a price-to-earnings ratio of -0.90 and a beta of 0.95.</p>
<div class="lb-trans"><p>AVTE 于星期五开盘价为 2.68 美元。Aerovate Therapeutics 的 52 周最低价为 1.25 美元，52 周最高价为 25.29 美元。该公司的 50 日移动平均线为 2.53 美元，200 日移动平均线也为 2.53 美元。该公司的市值为 7768 万美元，市盈率为-0.90，贝塔值为 0.95。</p>
</div><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last announced its earnings results on Friday, April 25th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.21. Equities analysts expect that Aerovate Therapeutics will post -2.64 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Aerovate Therapeutics（纳斯达克代码：AVTE - 获取免费报告）最后一次公布财报是在 4 月 25 日（星期五）。该公司报告本季度每股收益（EPS）为（0.09）美元，超出分析师一致预期的（0.30）美元，超出幅度为 0.21 美元。股票分析师预计 Aerovate Therapeutics 在当前财政年度将发布-2.64 的每股收益。</p>
</div><h2>Aerovate Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。该公司专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>O’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>高市盈率股票的比较与交易</li>
<li>德州仪器：盈利超预期，乐观指引推动复苏</li>
<li>3 只最佳金融科技股票，助力投资组合提升</li>
<li>O'Reilly Automotive：适合长期投资者的随时购买</li>
<li>消费品股票解析</li>
<li>Chipotle Mexican Grill 在第二季度提供了火热的入场点</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Aerovate Therapeutics 吗？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aerovate Therapeutics 并不在名单上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aerovate Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aerovate Therapeutics, Inc.（纳斯达克代码：AVTE）将发放 2.40 美元的股息